BioLine RX Ltd - ESG Rating & Company Profile powered by AI
The Disclosure score includes 17 United Nations SDGs including: 'Gender Equality', 'Climate Action' and 'Peace, Justice & Strong Institutions'. The webpage is a zero-cost E,S&G assessment for BioLine RX Ltd. Scroll down to the bottom of the webpage for potential risks for BioLine RX Ltd based on sector, location and size.
BioLine RX Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.9; made up of an environmental score of 0.0, social score of 4.8 and governance score of 4.0.
2.9
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1336 | SyneuRx International (Taiwan) Corp | 3.0 | Medium |
| 1336 | Sensorion SA | 3.0 | Medium |
| 1353 | BioLine RX Ltd | 2.9 | Medium |
| 1353 | Caribou Biosciences Inc | 2.9 | Medium |
| 1353 | Checkmate Pharmaceuticals Inc | 2.9 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does BioLine RX Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes BioLine RX Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes BioLine RX Ltd report the average age of the workforce?
Sign up for free to unlockDoes BioLine RX Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes BioLine RX Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes BioLine RX Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes BioLine RX Ltd offer flexible work?
Sign up for free to unlockDoes BioLine RX Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes BioLine RX Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes BioLine RX Ltd conduct supply chain audits?
Sign up for free to unlockDoes BioLine RX Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes BioLine RX Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes BioLine RX Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes BioLine RX Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes BioLine RX Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes BioLine RX Ltd disclose water use targets?
Sign up for free to unlockDoes BioLine RX Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid BioLine RX Ltd have a product recall in the last two years?
Sign up for free to unlockDoes BioLine RX Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes BioLine RX Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas BioLine RX Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes BioLine RX Ltd disclose parental leave metrics?
Sign up for free to unlockDoes BioLine RX Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes BioLine RX Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes BioLine RX Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes BioLine RX Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes BioLine RX Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes BioLine RX Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs BioLine RX Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes BioLine RX Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes BioLine RX Ltd disclose its waste policy?
Sign up for free to unlockDoes BioLine RX Ltd report according to TCFD requirements?
Sign up for free to unlockDoes BioLine RX Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes BioLine RX Ltd disclose energy use targets?
Sign up for free to unlockDoes BioLine RX Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes BioLine RX Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for BioLine RX Ltd
These potential risks are based on the size, segment and geographies of the company.
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.